What is Crossject?
Crossject Société Anonyme is a French company specializing in the development of innovative needle-free injection systems. Their flagship product, ZENEO, is designed for patient-administered self-injectables, targeting a range of critical medical conditions. The company's product pipeline includes treatments for epileptic seizures (Midazolam), opioid overdose (Naloxone), severe asthma crises (Terbutaline), anaphylactic shock (Epinephrine), migraines (Sumatriptan), and acute adrenal crisis (Hydrocortisone), as well as rheumatoid arthritis (Methotrexate). This diverse portfolio highlights Crossject's commitment to addressing significant unmet medical needs through advanced delivery technology.
How much funding has Crossject raised?
Crossject has raised a total of $36.7M across 4 funding rounds:
Debt
$12M
Unspecified
$7.6M
Other Financing Round
$11.3M
Debt
$5.8M
Debt (2020): $12M, investors not publicly disclosed
Unspecified (2024): $7.6M led by Agence nationale de la recherche ANR
Other Financing Round (2025): $11.3M supported by Biomedical Advanced Research and Development Authority (BARDA
Debt (2025): $5.8M featuring Vatel Capital
Key Investors in Crossject
Vatel Capital
Vatel Capital is an entity focused on financial planning and tax management services in France, assisting clients in optimizing their investments and reducing tax liabilities. Their involvement suggests a strategic financial backing for Crossject's growth initiatives.
Agence nationale de la recherche ANR
The Agence nationale de la recherche (ANR) is the French national agency dedicated to funding research projects across various scientific disciplines, with a focus on sustainable development and innovation. Their participation indicates support for Crossject's research and development efforts.
Biomedical Advanced Research and Development Authority (BARDA
BARDA is a U.S. government entity that supports the development of medical countermeasures for public health security threats. Their investment in Crossject suggests alignment with the company's mission to provide critical medical solutions, potentially for emergency preparedness.
What's next for Crossject?
With the recent major strategic investment and a history of substantial capital raises, Crossject appears to be in a scaling phase, likely focusing on advancing its product pipeline through clinical trials and preparing for commercialization. The enterprise-level funding suggests a strong investor confidence in the company's technology and market potential. Future strategic moves will likely involve expanding manufacturing capabilities, securing regulatory approvals, and establishing distribution partnerships to bring its needle-free solutions to a global market.
See full Crossject company page
